within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AX04_Dacarbazine;

model Dacarbazine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.133333333333333e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.00172,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00095,
    k12 = 8.15e-06,
    k21 = 8.15e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dacarbazine</td></tr><tr><td>ATC code:</td><td>L01AX04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.72</td><td>L</td></tr>
    <tr><td>clearance:</td><td>248</td><td>mL/min/m2</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dacarbazine is an antineoplastic agent classified as an alkylating agent, primarily used for the treatment of melanoma and Hodgkin's lymphoma. It interferes with DNA replication and transcription, leading to cell death. It is approved and used today mainly in chemotherapy protocols for these malignancies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult cancer patients, both sexes, typical age range for chemotherapy protocols.</p><h4>References</h4><ol><li><p>Patel, PM, et al., &amp; Spatz, A (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). <i>European journal of cancer (Oxford, England : 1990)</i> 47(10) 1476–1483. DOI:<a href=\"https://doi.org/10.1016/j.ejca.2011.04.030\">10.1016/j.ejca.2011.04.030</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21600759/\">https://pubmed.ncbi.nlm.nih.gov/21600759</a></p></li><li><p>Plummer, R, et al., &amp; Calvert, H (2013). A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. <i>Cancer chemotherapy and pharmacology</i> 71(5) 1191–1199. DOI:<a href=\"https://doi.org/10.1007/s00280-013-2113-1\">10.1007/s00280-013-2113-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23423489/\">https://pubmed.ncbi.nlm.nih.gov/23423489</a></p></li><li><p>Middleton, MR, et al., &amp; Thatcher, N (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 18(1) 158–166. DOI:<a href=\"https://doi.org/10.1200/JCO.2000.18.1.158\">10.1200/JCO.2000.18.1.158</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10623706/\">https://pubmed.ncbi.nlm.nih.gov/10623706</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01AX04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dacarbazine;
